--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Contracts
29.06.2012
Ad-hoc release
SYGNIS announces acquisition of a loan from BASF SE
Heidelberg, 29 June 2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard) today announces the execution of an agreement
effective 31 March 2012 with BASF SE to acquire a loan amounting to EUR
8,000,000 for a purchase price of EUR 1.00 which equals the fair value of the
loan. The loan was granted to SYGNIS Bioscience GmbH & Co. KG, a wholly-owned
subsidiary of SYGNIS Pharma AG. The acquisition of the loan is part of the
necessary realignment of the Company. BASF is a shareholder with approximately
11 per cent in SYGNIS Pharma AG.
The acquisition of the loan at fair value will be accounted through profit and
loss in the consolidated financial statements ended 31 March 2012.
The loan granted to SYGNIS Bioscience GmbH & Co. KG in September 2006 was due
for repayment on 30 June 2015. Interest was charged at the 3-month EURIBOR plus
a customary mark-up.
For further information please contact:
|Peter Willinger |
|Co-CEO/CFO |
|Tel: +49 (0) 6221-454 836 |
|Email: willinger@sygnis.de |
### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly
from the established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise these
statements in the light of new information or future results or for any other
reason.
###
Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English